What's happened
Companies like Kalshi are expanding prediction markets to biotech trials, linking drug trial outcomes to tradable contracts. Bloomberg and The Guardian report Kalshi’s pilot, its safeguards, and regulatory concerns, as markets push for open data on trial probabilities amid regulatory decisions.
What's behind the headline?
Context and stakes
- Kalshi is pushing for open datasets that reflect trial probabilities, potentially increasing transparency in drug development.
- The pilot aims to surface information that is often locked behind sponsor disclosures, but raises concerns about market manipulation and insider trading.
What could change
- Investors will be able to isolate regulatory outcomes from a company's stock movement, which may alter capital flows in biotech.
- Regulators are watching for safeguards and enforcement gaps as these markets scale.
Reader takeaway
- This mirrors broader trends toward data-enabled decision-making in healthcare, with risks around misuse and mispricing.
How we got here
Kalshi, a prediction market platform, is expanding to drug-trial outcomes in biotech. It launched 13 new contracts with AppliedXL to price regulatory events, following prior coverage of its trial-based bets and regulatory scrutiny.
Our analysis
Bloomberg reports Kalshi’s biotech contracts with AppliedXL, noting FDA regulatory decisions and the aim to price trial probabilities. The Guardian provides broader context on governance, safety safeguards, and concerns about manipulation. Bloomberg adds detail on prior and concurrent contracts tied to drug approvals.
Go deeper
- How might open trial probabilities affect conservation of patient recruitment?
- What safeguards are regulators considering to prevent manipulation?
- Will these markets influence投资 decisions in biotech funding?
More on these topics
-
Kalshi - American prediction market platform
Kalshi Inc. is a prediction market platform based in Manhattan, New York City, that launched in July 2021. The platform is used primarily for sports betting, which constitutes more than 90% of site activity and 89% of revenue in 2025. Analysts describe activity on the platform as "heavily tied to the sports calendar". Individuals can place bets on other future outcomes, including economic indicators, weather patterns, awards, political and legislative outcomes, and military conflicts. The site has been involved in several controversies and lawsuits regarding the legality of its sports and election markets, the ethics of allowing wagers on sensitive geopolitical issues, and insider trading involving politicians. Concerns over election integrity and declining public trust in the democratic process caused by election betting have been raised by consumer advocacy groups and politicians. As a result, the United States Senate banned its senators and their staff from betting on prediction markets such as Kalshi in May 2026. According to the site, there are 2.9 unprofitable users for each profitable one. Scholars have challenged whether Kalshi efficiently and accurately aggregates information...